Annovis Bio Inc (ANVS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Annovis Bio Inc (ANVS) has a cash flow conversion efficiency ratio of -2.883x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.01 Million) by net assets ($3.13 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Annovis Bio Inc worth for the company's overall valuation and market capitalisation.
Annovis Bio Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Annovis Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Annovis Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Annovis Bio Inc ranked by their cash flow conversion efficiency. See ANVS debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Freja eID Group AB
ST:FREJA
|
0.075x |
|
Shin Tai Industry Co Ltd
TW:1235
|
0.002x |
|
Kronos Bio Inc
NASDAQ:KRON
|
-0.161x |
|
Petros Petropoulos AEBE
AT:PETRO
|
-0.050x |
|
Integrated Logistics Bhd
KLSE:5614
|
-0.254x |
|
Zee Media Corporation Limited
NSE:ZEEMEDIA
|
0.290x |
|
US Masters Residential Property Fund
AU:URF
|
-0.040x |
|
Grupo Ezentis S.A
MC:EZE
|
-0.677x |
Annual Cash Flow Conversion Efficiency for Annovis Bio Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Annovis Bio Inc from 2009 to 2025. View current stock price of Annovis Bio Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $16.85 Million | $-25.62 Billion | -1520.344x | +35.37% |
| 2024-12-31 | $9.31 Million | $-21.89 Billion | -2352.325x | -45718.55% |
| 2023-12-31 | $-7.75 Million | $-39.97 Million | 5.157x | +943.59% |
| 2022-12-31 | $28.32 Million | $-17.31 Million | -0.611x | -197.82% |
| 2021-12-31 | $44.49 Million | $-9.13 Million | -0.205x | +61.02% |
| 2020-12-31 | $7.54 Million | $-3.97 Million | -0.527x | -1047.67% |
| 2019-12-31 | $-8.58 Million | $-476.54K | 0.056x | -24.46% |
| 2018-12-31 | $-7.59 Million | $-558.61K | 0.074x | -4.67% |
| 2017-12-31 | $-6.97 Million | $-537.48K | 0.077x | +114.53% |
| 2012-12-31 | $2.66 Million | $-1.41 Million | -0.531x | -145.69% |
| 2011-12-31 | $13.93 Million | $-3.01 Million | -0.216x | -100.99% |
| 2010-12-31 | $16.49 Million | $-1.77 Million | -0.108x | +59.22% |
| 2009-12-31 | $1.48 Million | $-389.23K | -0.264x | -- |
About Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury… Read more